Rolke James 4
4 · LA JOLLA PHARMACEUTICAL CO · Filed May 4, 2020
Insider Transaction Report
Form 4
Rolke James
Chief Scientific Officer
Transactions
- Award
Stock Option (Right to Buy)
2020-04-30+133→ 133 totalExercise: $7.26Exp: 2030-04-30→ Common Stock (133 underlying) - Award
Common Stock
2020-04-30$6.17/sh+133$821→ 81,426 total
Footnotes (2)
- [F1]These shares were acquired on 04/30/2020 through the La Jolla Pharmaceutical Company 2018 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F2]The stock option vests and becomes exercisable with respect to 25% of the underlying shares on the one-year anniversary of grant date and then vests and becomes exercisable ratably on a monthly basis over the next three years.